Manufacturing site rationalisation initiatives are becoming increasingly important in the current times of increased merger and acquisition (M&A) activity and product divestment. As pharmaceutical companies look to deliver short, medium and longterm efficiencies, the identification of potential synergies and efficiencies between multiple manufacturing sites has led to a marked increase in source transfer activities. This article reviews the numerous regulatory and logistical challenges and requirements inherent within a global manufacturing site rationalisation project.

Please download the free whitepaper for more information.